A downtrend has been apparent in Third Harmonic Bio, Inc. (THRD) lately with too much selling pressure. The stock has ...
Third Harmonic Bio, Inc. (THRD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm’s prior $18 ...
Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...
In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio (THRD) is initiating a process to identify opportunities to maximize ...
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value ...
1 Day THRD 1.94% DJIA 0.78% Russell 2K 0.40% Health Care/Life Sciences 1527.34% ...
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...